Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000685009 | SCV000812477 | uncertain significance | Cortical dysplasia-focal epilepsy syndrome | 2022-09-28 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 1309 of the CNTNAP2 protein (p.Ala1309Thr). This variant is present in population databases (rs530757880, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with CNTNAP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 565444). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004609484 | SCV005106528 | uncertain significance | Inborn genetic diseases | 2024-04-15 | criteria provided, single submitter | clinical testing | The c.3925G>A (p.A1309T) alteration is located in exon 24 (coding exon 24) of the CNTNAP2 gene. This alteration results from a G to A substitution at nucleotide position 3925, causing the alanine (A) at amino acid position 1309 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |